Gilead Sciences (NASDAQ:GILD) Given New $74.00 Price Target at Royal Bank of Canada

Gilead Sciences (NASDAQ:GILD – Free Report) had its target price lowered by Royal Bank of Canada from $76.00 to $74.00 in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock. A number of other research analysts also recently issued reports […]

Related Keywords

Canada ,United States ,Complera Eviplera ,Merdad Parsey ,Nilsine Partners ,Gilead Sciences ,Gilead Sciences Inc ,News Ratings For Gilead Sciences Daily ,Gilead Sciences Company Profile ,Gilead Sciences Trading ,Institutional Investors Weigh In On Gilead Sciences ,Barclays ,Royal Bank ,Financial Counselors Inc ,Nasdaq ,Analyst Recommendations For Gilead Sciences ,Wealth Partners ,Etesian Wealth Advisors Inc ,Institutional Family Asset Management ,Cantor Fitzgerald ,Gilead Sciences Dividend Announcement ,Free Report ,Get Free Report ,Wealth Advisors ,Family Asset Management ,Gilead Sciences Daily ,Nasdaq Gild ,Gild ,Medical ,37555810 ,Lower Price Target ,Royal Bank Of Canada ,